Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OR-1855

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BackgroundOrgan dysfunction consequent to infection (‘severe sepsis’) is the leading cause of admission to an intensive care unit… Expand
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Levosimendan enhances cardiac contractility via Ca(2+) sensitization and induces vasodilation through the activation of ATP… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Levosimendan enhances cardiac contractility primarily via Ca2+ sensitization, and it induces vasodilation through the activation… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
AIMS To determine the duration of haemodynamic and neurohormonal action of a 24-h infusion of levosimendan in heart failure… Expand
Is this relevant?
Review
2007
Review
2007
Levosimendan has been developed for the treatment of decompensated heart failure and is used intravenously when patients with… Expand
Is this relevant?
2007
2007
Background and objectivesLevosimendan is a calcium sensitiser developed for the treatment of congestive heart failure. It… Expand
Is this relevant?
2004
2004
AIMS The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in… Expand
  • table 1
  • table 2
Is this relevant?
2004
2004
OBJECTIVE The purpose of this study was to investigate the pharmacokinetics of levosimendan and to determine the primary… Expand
Is this relevant?
1999
1999
Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters… Expand
Is this relevant?
1998
1998
BACKGROUND Levosimendan is a new calcium sensitizer, acting calcium-dependently on cardiac troponin C. In the present study… Expand
Is this relevant?